Boston Scientific is expanding its portfolio of blood blocking product with the purchase of Obsidio and its Gel Embolic Material (GEM) technology that is used for embolization of blood vessels in the peripheral vasculature.

The gel-like material is delivered through a catheter in a minimally invasive procedure to obstruct or reduce blood flow to an abnormality or tumor to stop hemorrhaging, reduce the size of malignant and benign tumors and stabilize venous and arterial malformations.

The GEM device, which has already been cleared by the FDA, is a semi-solid material packaged in a ready-to-use form that reduces the preparation time required for the embolization procedures.

The financial terms of the acquisition were not disclosed.